Innovation Digest – July 2018 vol. 1

In a value-focused healthcare system, transparency of cost and evidence of effectiveness is crucial to making good choices. Patients face significant challenges in both cases and traditionally rely on their clinicians and providers to help them match their unique needs and situation with best available evidence and treatment options. The elimination of a national resource for clinical guideline dissemination and ongoing finger-pointing within the pharma-PBM-payer communities are detrimental to that partnership. Fresh thinking from the FDA and others about the role of real-world evidence and the need to accelerate dissemination and transparency initiatives is promising. Who will join this bandwagon?

In this issue:

  • FDA Budget Matters: A Cross-Cutting Data Enterprise for Real World Evidence
  • Trump administration is shutting down practice-guidelines clearinghouse for doctors
  • Shift to value-based care could leave some patient groups behind
  • Michael Dowling: The urgency of change
  • New partnership aims to launch employer bundled payment programs
  • Value-based models haven’t reduced costs yet, study finds
  • Patients want better communication, care coordination, survey shows
Back to Viewpoint